Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
- DOI
- 10.1002/edm2.70298
- Published
- 2026 Sep
- Container
- Endocrinology, diabetes & metabolism
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/edm2.70298,
title = {Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.},
author = {Mohamed ZI and Shidane AA and Abdiasis AM and Hussein MH and Ibrahim AO and Abdi AA and Hashi KI and Mohamud MA and Mohamed AJ},
year = {2026},
journal = {Endocrinology, diabetes \& metabolism},
doi = {10.1002/edm2.70298},
url = {https://doi.org/10.1002/edm2.70298}
}RIS
TY - JOUR TI - Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era. AU - Mohamed ZI AU - Shidane AA AU - Abdiasis AM AU - Hussein MH AU - Ibrahim AO AU - Abdi AA AU - Hashi KI AU - Mohamud MA AU - Mohamed AJ PY - 2026 JO - Endocrinology, diabetes & metabolism DO - 10.1002/edm2.70298 UR - https://doi.org/10.1002/edm2.70298 ER -
APA
ZI, M., AA, S., AM, A., MH, H., AO, I., AA, A., KI, H., MA, M., & AJ, M. (2026). Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.. Endocrinology, diabetes & metabolism. https://doi.org/10.1002/edm2.70298
Source records
- pubmed · retrieved 2026-09-25T15:34:15.619Z